Significant biosimilar activities this week include:
01 April 2023 | AU | Humira® 24.39% PBS price drop
30 March 2023 | EU | EMA CHMP gives nod to Samsung Bioepis’ Epysqli™ eculizumab biosimilar
29 March 2023 | AU | Cipla/Alvotech’s biosimilar adalimumab and Juno’s biosimilar enoxaparin on AU PBAC Agenda for July 23
27 March 2023 | US | US Supreme Court hears oral submissions in Amgen Inc v Sanofi evolocumab/alirocumab dispute with decision on ‘enablement’ expected
27 March 2023 | EU | IE | Eli Lilly announced US$1B investment in new Irish monoclonal antibody manufacturing facility
27 March 2023 | JP | Approval alert: Daiichi Sankyo’s Enhertu® (trastuzumab deruxtecan) approved in Japan for HER2 low metastatic breast cancer
20 March 2023 | Coya and Dr Reddy’s enter exclusive worldwide agreement to develop COYA 302 (abatacept + COYA 301)